How to use this tool
How to use this tool
InvestorGuide Stock Analysis
Will Shareholders Agree to Sell Genentech?
Excerpt from the InvestorGuide.com Stock of the Day on 2/2/2009
About six months ago, Swiss drugmaker Roche offered to buy out all of Genentech's remaining stock in a deal worth $44 billion. This equals about $89 per share. This represented a 9 percent premium at the time. The board of directors evaluated this offer and about a month later, rejected the bid saying the price significantly undervalued the company's worth and growth potential. Little else has occurred since, but on Friday, Roche took the deal directly to shareholders asking to buy their equity for $86.50 per share. The US biotech firm advised shareholders not to take action so it can review its current position and prepare a formal response. Investors and analysts expect an announcement within two weeks. By the end of Friday, Genentech's stock closed at $81.50, indicating investors are complying. Having been rejected once by the company, will Roche be rejected a second time by shareholders? More >
Excerpt from the InvestorGuide.com Stock of the Day on 2/2/2009
About six months ago, Swiss drugmaker Roche offered to buy out all of Genentech's remaining stock in a deal worth $44 billion. This equals about $89 per share. This represented a 9 percent premium at the time. The board of directors evaluated this offer and about a month later, rejected the bid saying the price significantly undervalued the company's worth and growth potential. Little else has occurred since, but on Friday, Roche took the deal directly to shareholders asking to buy their equity for $86.50 per share. The US biotech firm advised shareholders not to take action so it can review its current position and prepare a formal response. Investors and analysts expect an announcement within two weeks. By the end of Friday, Genentech's stock closed at $81.50, indicating investors are complying. Having been rejected once by the company, will Roche be rejected a second time by shareholders? More >
MAKO Surgical (MAKO) Upgrades
Date
Analyst
Old Rating
New Rating
No upgrades listed for MAKO at this time.
MAKO Surgical (MAKO) Downgrades
Date
Analyst
Old Rating
New Rating
10/30/2009
Lazard Capital
Buy
Hold
MAKO Surgical (MAKO) New Coverage
Date
Analyst
Rating
08/25/2009
Leerink Swann
Market Perform
03/11/2009
Ladenburg Thalmann
Buy
10/02/2008
Piper Jaffray
Buy
09/04/2008
Lazard Capital
Buy
09/04/2008
Lazard
Buy
03/26/2008
Wachovia
Market Perform
Special Offers
| Buy MAKO Surgical for just $4 www.sharebuilder.com |
| What is Morningstar's rating for MAKO Surgical? www.morningstar.com |
| Learn to spot opportunities in any market with a Risk-Free* 30-day trial from Investools. www.investools.com |
| Trade Forex with FXSolutions. Sign up for FREE $10,000 Practice Account. www.fxsolutions.com |
| Download a free Options Fundamentals Podcast, from The Options Industry Council. OptionsEducation.org |
MAKO Links
Guru Analysis:
MSN Money | Morningstar | Stock Consultant
Analyst Opinions:
Reuters | SmartMoney | MarketWatch | Nasdaq | BarChart | Schaeffers | CNN Money | TheStreet
Blogs:
SocialPicks | Topix.net | SeekingAlpha | Technorati | Ask.com
Message Boards:
ClearStation | RagingBull | Yahoo | Investopedia | FreeRealTime | StockHouse Trading Offers:
Buy MAKO for just $4
MSN Money | Morningstar | Stock Consultant
Analyst Opinions:
Reuters | SmartMoney | MarketWatch | Nasdaq | BarChart | Schaeffers | CNN Money | TheStreet
Blogs:
SocialPicks | Topix.net | SeekingAlpha | Technorati | Ask.com
Message Boards:
ClearStation | RagingBull | Yahoo | Investopedia | FreeRealTime | StockHouse Trading Offers:
Buy MAKO for just $4
